| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Sorafenib in advanced clear-cell renal-cell carcinoma.
|
N Engl J Med
|
2007
|
30.94
|
|
2
|
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
|
J Clin Oncol
|
2009
|
6.86
|
|
3
|
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
|
J Clin Oncol
|
2006
|
6.77
|
|
4
|
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
|
J Clin Oncol
|
2008
|
6.23
|
|
5
|
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
|
J Natl Cancer Inst
|
2007
|
5.13
|
|
6
|
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
|
J Clin Oncol
|
2010
|
5.08
|
|
7
|
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
|
J Clin Oncol
|
2004
|
4.67
|
|
8
|
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
|
J Clin Oncol
|
2004
|
4.25
|
|
9
|
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
|
J Clin Oncol
|
2012
|
3.73
|
|
10
|
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
|
J Clin Oncol
|
2005
|
3.28
|
|
11
|
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
|
J Clin Oncol
|
2008
|
3.00
|
|
12
|
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
J Clin Oncol
|
2003
|
2.85
|
|
13
|
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
|
J Clin Oncol
|
2009
|
2.69
|
|
14
|
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
|
Cancer
|
2013
|
2.61
|
|
15
|
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
|
J Clin Oncol
|
2011
|
2.46
|
|
16
|
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
|
Clin Cancer Res
|
2010
|
2.44
|
|
17
|
A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.
|
Eur Urol
|
2009
|
2.26
|
|
18
|
Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site.
|
J Urol
|
2003
|
2.12
|
|
19
|
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.
|
J Clin Oncol
|
2011
|
2.10
|
|
20
|
A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.
|
Cancer
|
2014
|
2.05
|
|
21
|
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
|
Clin Cancer Res
|
2009
|
1.93
|
|
22
|
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
|
J Clin Oncol
|
2008
|
1.74
|
|
23
|
Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging.
|
Radiology
|
2010
|
1.70
|
|
24
|
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.
|
Cancer
|
2011
|
1.70
|
|
25
|
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.
|
Cancer
|
2009
|
1.70
|
|
26
|
An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease.
|
Clin Cancer Res
|
2008
|
1.68
|
|
27
|
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
|
Eur Urol
|
2012
|
1.66
|
|
28
|
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.
|
Urology
|
2010
|
1.65
|
|
29
|
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
|
Eur Urol
|
2012
|
1.64
|
|
30
|
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
|
Biol Blood Marrow Transplant
|
2006
|
1.63
|
|
31
|
Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.
|
Clin Cancer Res
|
2005
|
1.59
|
|
32
|
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results.
|
J Clin Oncol
|
2002
|
1.56
|
|
33
|
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.
|
J Magn Reson Imaging
|
2004
|
1.54
|
|
34
|
Estimating the arterial input function using two reference tissues in dynamic contrast-enhanced MRI studies: fundamental concepts and simulations.
|
Magn Reson Med
|
2004
|
1.50
|
|
35
|
A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation.
|
Cancer
|
2007
|
1.47
|
|
36
|
Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis.
|
AJR Am J Roentgenol
|
2011
|
1.45
|
|
37
|
MR imaging-guided focal laser ablation for prostate cancer: phase I trial.
|
Radiology
|
2013
|
1.38
|
|
38
|
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
|
J Clin Oncol
|
2012
|
1.37
|
|
39
|
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
|
Invest New Drugs
|
2007
|
1.37
|
|
40
|
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.
|
Clin Cancer Res
|
2009
|
1.30
|
|
41
|
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
|
Gynecol Oncol
|
2008
|
1.29
|
|
42
|
Multiple reference tissue method for contrast agent arterial input function estimation.
|
Magn Reson Med
|
2007
|
1.27
|
|
43
|
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
|
Cancer
|
2010
|
1.23
|
|
44
|
FYN is overexpressed in human prostate cancer.
|
BJU Int
|
2008
|
1.22
|
|
45
|
Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7.
|
Cancer Res
|
2005
|
1.21
|
|
46
|
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
|
J Clin Pharmacol
|
2013
|
1.21
|
|
47
|
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
|
J Clin Oncol
|
2004
|
1.20
|
|
48
|
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.
|
Cancer
|
2009
|
1.19
|
|
49
|
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
|
Clin Cancer Res
|
2013
|
1.19
|
|
50
|
Randomized phase II trials: a long-term investment with promising returns.
|
J Natl Cancer Inst
|
2011
|
1.17
|
|
51
|
Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy.
|
Urology
|
2008
|
1.15
|
|
52
|
Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence.
|
J Am Med Inform Assoc
|
2011
|
1.12
|
|
53
|
Resampling phase III data to assess phase II trial designs and endpoints.
|
Clin Cancer Res
|
2012
|
1.11
|
|
54
|
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
|
Clin Cancer Res
|
2014
|
1.09
|
|
55
|
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
|
Invest New Drugs
|
2010
|
1.09
|
|
56
|
Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review.
|
Cancer
|
2007
|
1.07
|
|
57
|
Gene expression profiling of renal medullary carcinoma: potential clinical relevance.
|
Cancer
|
2004
|
1.06
|
|
58
|
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.
|
Urology
|
2011
|
1.06
|
|
59
|
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.
|
BJU Int
|
2010
|
1.03
|
|
60
|
Recommended changes to oncology clinical trial design: revolution or evolution?
|
Eur J Cancer
|
2007
|
1.03
|
|
61
|
Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma.
|
Am J Clin Oncol
|
2013
|
1.03
|
|
62
|
Innovations and challenges in renal cancer: consensus statement from the first international conference.
|
Clin Cancer Res
|
2004
|
1.02
|
|
63
|
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
|
Cancer
|
2002
|
0.98
|
|
64
|
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
|
Cancer
|
2013
|
0.98
|
|
65
|
Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis.
|
Magn Reson Med
|
2009
|
0.97
|
|
66
|
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
|
Clin Cancer Res
|
2005
|
0.96
|
|
67
|
Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer.
|
Crit Rev Oncol Hematol
|
2010
|
0.96
|
|
68
|
Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study.
|
J Clin Oncol
|
2009
|
0.95
|
|
69
|
Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers.
|
Prostate
|
2011
|
0.95
|
|
70
|
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
|
Cancer
|
2013
|
0.94
|
|
71
|
Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study.
|
Urology
|
2011
|
0.93
|
|
72
|
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.
|
Invest New Drugs
|
2011
|
0.93
|
|
73
|
Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signatures.
|
J Am Med Inform Assoc
|
2011
|
0.93
|
|
74
|
A Phase II study of oxaliplatin in urothelial cancer.
|
Urol Oncol
|
2005
|
0.92
|
|
75
|
Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.91
|
|
76
|
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
|
Oncology
|
2010
|
0.91
|
|
77
|
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer.
|
BJU Int
|
2008
|
0.91
|
|
78
|
Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder.
|
J Surg Oncol
|
2015
|
0.91
|
|
79
|
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
|
BJU Int
|
2007
|
0.91
|
|
80
|
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
|
Clin Cancer Res
|
2004
|
0.90
|
|
81
|
Low-grade prostate cancer diverges early from high grade and metastatic disease.
|
Cancer Sci
|
2014
|
0.90
|
|
82
|
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
|
Clin Cancer Res
|
2006
|
0.90
|
|
83
|
FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.
|
Cancer Med
|
2013
|
0.90
|
|
84
|
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
|
J Clin Oncol
|
2008
|
0.90
|
|
85
|
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
|
Lung Cancer
|
2012
|
0.89
|
|
86
|
A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.
|
Cancer Biol Ther
|
2007
|
0.88
|
|
87
|
Adjuvant chemotherapy in lymph node positive bladder cancer.
|
Urol Oncol
|
2008
|
0.87
|
|
88
|
The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
|
Horm Cancer
|
2014
|
0.87
|
|
89
|
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
|
BJU Int
|
2014
|
0.86
|
|
90
|
A phase I study of continuous infusion cilengitide in patients with solid tumors.
|
Invest New Drugs
|
2010
|
0.86
|
|
91
|
A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
|
BJU Int
|
2005
|
0.85
|
|
92
|
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
|
Invest New Drugs
|
2006
|
0.85
|
|
93
|
A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer.
|
Clin Genitourin Cancer
|
2008
|
0.84
|
|
94
|
Predictive markers in advanced renal cell carcinoma.
|
Semin Oncol
|
2013
|
0.83
|
|
95
|
Pazopanib in renal cell carcinoma.
|
Clin Cancer Res
|
2010
|
0.83
|
|
96
|
The role of chemotherapy in upper tract urothelial carcinoma.
|
Adv Urol
|
2009
|
0.83
|
|
97
|
Comparison of quantitative parameters in cervix cancer measured by dynamic contrast-enhanced MRI and CT.
|
Magn Reson Med
|
2010
|
0.82
|
|
98
|
New targets, therapies, and toxicities: lessons to be learned.
|
J Clin Oncol
|
2005
|
0.82
|
|
99
|
A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer.
|
Urol Oncol
|
2004
|
0.82
|
|
100
|
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma.
|
Cancer
|
2008
|
0.82
|
|
101
|
Gene expression profiling in kidney cancer: combining differential expression and chromosomal and pathway analyses.
|
Clin Genitourin Cancer
|
2006
|
0.81
|
|
102
|
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
|
Invest New Drugs
|
2006
|
0.81
|
|
103
|
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
|
Curr Oncol Rep
|
2005
|
0.81
|
|
104
|
Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer.
|
Clin Genitourin Cancer
|
2006
|
0.80
|
|
105
|
A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
|
BJU Int
|
2005
|
0.80
|
|
106
|
Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer.
|
Clin Genitourin Cancer
|
2008
|
0.80
|
|
107
|
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
|
Curr Urol Rep
|
2006
|
0.80
|
|
108
|
Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.
|
Clin Genitourin Cancer
|
2008
|
0.80
|
|
109
|
Bevacizumab and everolimus in renal cancer: a rational way forward.
|
J Clin Oncol
|
2010
|
0.80
|
|
110
|
Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma.
|
Clin Genitourin Cancer
|
2009
|
0.80
|
|
111
|
Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?
|
Clin Cancer Res
|
2012
|
0.80
|
|
112
|
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
|
J Cancer Surviv
|
2011
|
0.80
|
|
113
|
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
|
Cancer
|
2002
|
0.79
|
|
114
|
Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy.
|
Nat Rev Urol
|
2010
|
0.79
|
|
115
|
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
|
Cancer
|
2004
|
0.79
|
|
116
|
Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial.
|
Clin Genitourin Cancer
|
2006
|
0.78
|
|
117
|
Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity.
|
J Immunother
|
2002
|
0.78
|
|
118
|
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
|
Am J Clin Oncol
|
2011
|
0.78
|
|
119
|
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
|
Am J Clin Oncol
|
2005
|
0.77
|
|
120
|
Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.77
|
|
121
|
Prognostic factors in localized renal cell cancer.
|
BJU Int
|
2007
|
0.77
|
|
122
|
The role of systemic chemotherapy in the treatment of kidney cancer.
|
Cancer Treat Res
|
2003
|
0.76
|
|
123
|
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
|
Prostate
|
2009
|
0.76
|
|
124
|
Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial Design.
|
Am Stat
|
2012
|
0.76
|
|
125
|
The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer.
|
Cancer J
|
2016
|
0.76
|
|
126
|
Effective therapy for metastatic renal cancer, whither to now.
|
J Clin Oncol
|
2009
|
0.75
|
|
127
|
Prognosis and prediction in a Facebook world.
|
Cancer
|
2009
|
0.75
|
|
128
|
Do elderly patients have a worse outcome in response to platinum-based therapy for metastatic urothelial cancer?
|
Nat Clin Pract Oncol
|
2005
|
0.75
|
|
129
|
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
|
J Clin Oncol
|
2005
|
0.75
|
|
130
|
Metastasis suppressor genes: signal transduction, cross-talk and the potential for modulating the behavior of metastatic cells.
|
Anticancer Drugs
|
2004
|
0.75
|
|
131
|
A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer.
|
Eur Urol
|
2012
|
0.75
|